Editas Medicine, Inc. (EDIT) is listed on NasdaqGS in the Healthcare sector Β· Biotechnology industry. The current price is 3.04, down -1.30% from the previous close. Market cap is approximately $466.9M.
The commentary below is auto-generated by comparing market data (P/E, ROE, D/E, etc.) against predefined thresholds. No LLM is used. This is not a buy/sell recommendation from us or any analyst. For reference only.
A low ROE of -118.82% is common in capital-heavy sectors (utilities, heavy industry, infrastructure) or after large equity raises.
D/E of 14.73 indicates high leverage. Watch interest coverage and free cash flow closely, especially across rate cycles.
Revenue is growing 232.30% year-over-year. Double-digit growth often reflects share gains or new-market entry.
Demographic-driven structural demand growth is a long-running tailwind for healthcare.
Editas Medicine, Inc. trades near the midpoint (52%) of its 52-week range (1.66β4.54). With the price anchored to neither extreme, valuation and earnings tend to be more informative than price direction here.
The day's high-to-low spread reached 4.33%, with a -1.30% move. Wide sessions frequently follow earnings, filings, or sector news, so identifying the catalyst matters.
Editas Medicine, Inc. (EDIT) is listed on NasdaqGS, with recent volume of 637,844 shares. Volume is a supporting gauge of how much conviction sits behind a price move β the same gain reads differently on heavy versus light turnover.
Your watchlist and portfolio, one tap from your home screen β the Margin Call app